Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223

Radium-223 is a first-in-class alpha particle-emitting radiopharmaceutical approved for the treatment of bone metastatic castration-resistant prostate cancer. Radium-223 is administered intravenously with no requirement for complex shielding and specifically targets areas of bone metastasis. In a ra...

Full description

Saved in:
Bibliographic Details
Main Authors: Mukherji, Deborah, El Dika, Imane, Temraz, Sally, Haidar, Mohammed, Shamseddine, Ali
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2014
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4043797/
https://ncbi.nlm.nih.gov/pubmed/24920911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S45667
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items